Literature DB >> 26721492

Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.

Hiroto Hatakeyama1, Sherry Y Wu1, Lingegowda S Mangala1,2, Gabriel Lopez-Berestein2,3,4, Anil K Sood5,6,7.   

Abstract

RNA interference (RNAi) has rapidly become a powerful tool for target discovery and therapeutics. Small interfering RNAs (siRNAs) are highly effective in mediating sequence-specific gene silencing. However, the major obstacle for using siRNAs as cancer therapeutics is their systemic delivery from the administration site to target cells in vivo. This chapter describes approaches to deliver siRNA effectively for cancer treatment and discusses in detail the current methods to assess pharmacokinetics and biodistribution of siRNAs in vivo.

Entities:  

Keywords:  Cancer therapy; Delivery; Ovarian cancer; Stem-loop RT-PCR; siRNA

Mesh：

Substances：

Year:  2016        PMID： 26721492      PMCID： PMC5142631          DOI： 10.1007/978-1-4939-3378-5_15

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  19 in total

Review 1.  In vivo near-infrared fluorescence imaging.

Authors:  John V Frangioni
Journal:  Curr Opin Chem Biol       Date:  2003-10       Impact factor: 8.822

2.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

3.  Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer.

Authors:  Kshipra M Gharpure; Kevin S Chu; Charles J Bowerman; Takahito Miyake; Sunila Pradeep; Selanere L Mangala; Hee-Dong Han; Rajesha Rupaimoole; Guillermo N Armaiz-Pena; Tojan B Rahhal; Sherry Y Wu; J Christopher Luft; Mary E Napier; Gabriel Lopez-Berestein; Joseph M DeSimone; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2014-04-22       Impact factor: 6.261

4.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.

Authors:  S M Elbashir; J Harborth; W Lendeckel; A Yalcin; K Weber; T Tuschl
Journal:  Nature       Date:  2001-05-24       Impact factor: 49.962

Review 5.  RNA interference in the clinic: challenges and future directions.

Authors:  Chad V Pecot; George A Calin; Robert L Coleman; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Nat Rev Cancer       Date:  2010-12-16       Impact factor: 60.716

Review 6.  A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma.

Authors:  Hiroto Hatakeyama; Hidetaka Akita; Hideyoshi Harashima
Journal:  Adv Drug Deliv Rev       Date:  2010-09-15       Impact factor: 15.470

Review 7.  Imaging of angiogenesis: from microscope to clinic.

Authors:  Donald M McDonald; Peter L Choyke
Journal:  Nat Med       Date:  2003-06       Impact factor: 53.440

8.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

Authors:  Y Matsumura; H Maeda
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

9.  Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size.

Authors:  H Cabral; Y Matsumoto; K Mizuno; Q Chen; M Murakami; M Kimura; Y Terada; M R Kano; K Miyazono; M Uesaka; N Nishiyama; K Kataoka
Journal:  Nat Nanotechnol       Date:  2011-10-23       Impact factor: 40.523

10.  Real-time quantification of microRNAs by stem-loop RT-PCR.

Authors:  Caifu Chen; Dana A Ridzon; Adam J Broomer; Zhaohui Zhou; Danny H Lee; Julie T Nguyen; Maura Barbisin; Nan Lan Xu; Vikram R Mahuvakar; Mark R Andersen; Kai Qin Lao; Kenneth J Livak; Karl J Guegler
Journal:  Nucleic Acids Res       Date:  2005-11-27       Impact factor: 16.971
View more
  2 in total

1.  Targeted in vivo delivery of EGFR siRNA inhibits ovarian cancer growth and enhances drug sensitivity.

Authors:  Minati Satpathy; Roman Mezencev; Lijuan Wang; John F McDonald
Journal:  Sci Rep       Date:  2016-11-07       Impact factor: 4.379

2.  A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.

Authors:  Sherry Y Wu; Rajesha Rupaimoole; Fangrong Shen; Sunila Pradeep; Chad V Pecot; Cristina Ivan; Archana S Nagaraja; Kshipra M Gharpure; Elizabeth Pham; Hiroto Hatakeyama; Michael H McGuire; Monika Haemmerle; Viviana Vidal-Anaya; Courtney Olsen; Cristian Rodriguez-Aguayo; Justyna Filant; Ehsan A Ehsanipour; Shelley M Herbrich; Sourindra N Maiti; Li Huang; Ji Hoon Kim; Xinna Zhang; Hee-Dong Han; Guillermo N Armaiz-Pena; Elena G Seviour; Sue Tucker; Min Zhang; Da Yang; Laurence J N Cooper; Rouba Ali-Fehmi; Menashe Bar-Eli; Ju-Seog Lee; Prahlad T Ram; Keith A Baggerly; Gabriel Lopez-Berestein; Mien-Chie Hung; Anil K Sood
Journal:  Nat Commun       Date:  2016-04-04       Impact factor: 14.919
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.